Time-dose considerations in the treatment of anal cancer
Open Access
- 1 October 1997
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 39 (3) , 651-657
- https://doi.org/10.1016/s0360-3016(97)00329-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.Journal of Clinical Oncology, 1996
- Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): An eastern cooperative oncology group studyInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Ten-year results of chemoradiation for anal cancer: Focus on late morbidityInternational Journal of Radiation Oncology*Biology*Physics, 1996
- 33 Dose acceleration in chemoradiation (CRX) for anal cancer: Preliminary results of RTOG 92-08International Journal of Radiation Oncology*Biology*Physics, 1995
- Squamous-cell carcinoma of the anus in HIV-positive patientsDiseases of the Colon & Rectum, 1994
- Chemoradiotherapy for anal carcinoma: What is the optimal radiation dose?Radiation Oncology Investigations, 1994
- Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin CInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Anal cancerInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Radiotherapy for anal cancer: Experience from 1979–1987International Journal of Radiation Oncology*Biology*Physics, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958